Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia

Journal of Hypertension

Volumn 30, Issue 11, 2012, Pages 2173-2181

  Leaños Miranda, Alfredo ^a   Campos Galicia, Inova ^a   Isordia Salas, Irma ^c   Rivera Leaños, Roxana ^a   Romero Arauz, Juan Fernando ^b   Ayala Méndez, José Antonio ^b   Ulloa Aguirre, Alfredo ^a  

^a Research Unit in Reproductive Medicine   (Mexico)

^b UMAE Hospital de Ginecología y Obstetricia Luis Castelazo Ayala   (Mexico)

^c Hospital General Regional Gabriel Mancera   (Mexico)

Author keywords

biomarkers; placental growth factor; prediction; preeclampsia; pregnancy; soluble fms like tyrosine kinase 1

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; LUMINESCENCE; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL;

EID: 84867744713     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328357c0c9     Document Type: Article

References (30)

1. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16:5-15.
2. Chesley LC. Diagnosis of preeclampsia. Obstet Gynecol 1985; 65:423-425.
3. National High Blood Pressure Education Program. Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183:S1-S22.
4. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gyne-col 2000; 95:24-28.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclamp-sia. J Clin Invest 2003; 111:649-658.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
7. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90:10705-10709.
8. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) premRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999; 13:537-545.
9. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280:C1358-C1366.
10. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88:2348-2351.
11. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors clusters hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005; 192:734-741.
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al., CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factor in preeclampsia. N Engl J Med 2006; 355:992-1005.
13. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293:77-85.
14. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, et al., for the Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLOS One 2010; 5:e13263.
15. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202:161.e1-161.e11.
16. Ohkuchi A, Hirashima Ch, Suzuki H, Takahashi K, Yoshida M, Matsu-bara S, Suzuki M. Evaluation of a new and automated electrochemi-luminescence immunoassay for plasma sFlt-1 and PIGF levels in women with preeclampsia. Hypertens Res 2010; 33:422-427.
17. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33. Obstet Gynecol 2002; 99:159-167.
18. Leaños-Miranda A, Márquez-Acosta J, Romero-Arauz F, Cárdenas-Mondragón MG, Rivera-Leaños R, Isordia-Salas I, Ulloa-Aguirre A. Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-h protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clin Chem 2007; 53:1623-1628.
19. Zhang J, Bowes WA Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995; 86:200-208.
20. Schneider E, Gleixner A, Hänel R, Leyhe Y, Kleinschmidt C, Beck G, et al. Technical performance of the first fully automated assays for soluble fms-like tyrosine kinase and human p1acental growth factor. Z Geburtshilfe Neonatol 2009; 213:69.
21. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21:9-23.
22. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010; 43:768-770.
23. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112:51-57.
24. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004; 51:251-268.
25. Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet 2012; 285:417-422.
26. Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007; 197:211.e1-211.e4.
27. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical pre-eclampsia. Am J Obstet Gynecol 2001; 184:1267-1272.
28. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23:101-111.
29. Vatten LJ, Eskild A, Nilsen TIL, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196:239; e1-239.e6.
30. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010; 376:631-644.